Shaily Engineering Plastics Ltd

Meeting Details

• Date & time: 21 August 2026, 10:00 AM onwards
• Nature: Group meeting
• Venue: Baroda, Gujarat (physical)
• Organiser: Shaily Engineering Plastics Ltd

Participants

• Company Secretary & Compliance Officer

Purpose

• Investor/analyst interaction based on publicly available information

Additional Notes

• Changes may occur due to host/Company exigencies

Financial Performance

• Consolidated revenue for Q1 FY27: INR 281 crores, up 14% YoY.
• EBITDA: INR 83 crores; margin 29.7%; up 18% YoY.
• PAT: INR 48 crores; margin 17.1%; up 17% YoY.
• Healthcare revenue: INR 142 crores; 51% of consolidated; up 85% YoY.
• Consumer revenue: INR 116 crores; 41% of consolidated; down 24% YoY.
• Industrial revenue: INR 23 crores; up 25% YoY.
• Machine utilization: 50.2% in Q1 FY27 vs 48.7% QoQ LY.
• Exports share: 58% of consolidated revenue vs 76% LY Q1.
• Pen capacity added: 25 million; total ~75 million pens/annum; by end Sep 2026.

Segment Update

• Healthcare growth led by pen injector platform; orders after Semaglutide approvals in Canada, Brazil.
• Consumer: softer Home Furnishings demand in Europe/US; new FMCG project; 5 LED components won.
• Industrial: revenue up 25%; new projects from Appliance and Automotive; 5 consumer-electronics components ordered.
• Global BD heads appointed for Europe and North America to pursue partnerships.

Capex and Projects

• Pen injector capacity: +25 million; total ~75 million pens/annum; operational by end of September.
• Consumer Electronics: started commercial supply; 5 components; new customer; supply before end of FY; land secured.
• Abu Dhabi capacity: 50–55% commitments; commercial sales by FY28; Europe openings in 2028; other markets 2030–31.
• Semiconductor Trays capex: ~INR 5 crores in existing facility.
• Emergency-use auto-injectors: development to close by end FY27; reliability target 99.999%.
• On-body Mira development: partnerships; potential announcements in next ~6 quarters.
• Two regional heads to drive growth in Europe and US.

Outlook and Guidance

• Pen guidance of 36 million; management notes potential to beat and go beyond 36 million.
• Gross margin to normalize back to pre-war levels by Q3 FY27.
• Abu Dhabi plant: commercial sales by end FY28; Europe 2028; insulin/other markets 2030–31.
• Consumer Electronics ramp expected; potential to reach $10 million revenue in 24–30 months (not formal guidance).
• Semiconductor Trays capex confirmed at INR 5 crores.

Q&A Highlights

• 1Q pens: ~9 million devices; GLP-1 ~50–60% mix; rest insulin/other therapies.
• Line-2 ramp: 9% speed gain; further ~30% jump after additional equipment; end of this quarter.
• GUIDANCE: still aiming to beat 36 million pens if execution remains favorable.
• Consumer Electronics: 5 components; ramp to broader ecosystem; 24–30 months to ~$10m revenue.
• UK revenue timing issue; expect recovery over next 3 quarters.
• Emergency-use auto-injectors to be showcased at CPHI Milan; reliability emphasized.

Meeting Details

• Earnings call held on 10 August 2026; audio recording uploaded on the company website.
• Transcript to be submitted separately.
• Purpose: earnings call for discussion of quarterly results with investors.

Dematerialisation processing and listing

• Dematerialisation requests received up to 30 June 2026 were confirmed to depositories as accepted or rejected.
• Securities dematerialised have been listed on the stock exchange where the earlier issued securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled after verification.
• Depository name substituted as registered owner within 15 days of receipt.

Meeting Details

• Dates: 13th and 14th July 2026, 10:00 AM to 6:00 PM.
• Type/Format: 1x1 and group meetings; venue in London, UK.
• Organised by: UBS.
• Key company participant: Company Secretary & Compliance Officer.
• Purpose: Discussions will be based on publicly available information.
• UPSI: No unpublished price sensitive information intended to be discussed.